FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2564387316> ?p ?o ?g. }

• W2564387316 abstract "Abstract Abstract 1173 Severe inherited factor XI (FXI) deficiency decreases the risk of ischemic thromboembolic stroke and deep vein thrombosis, but can also cause bleeding in some patients. We therefore sought to further explore the roles of FXI in hemostasis and thrombosis in a baboon model, utilizing the anticoagulant monoclonal antibodies 14E11 and 1A6 that target specific functional domains of FXI. The 14E11 antibody binds to the apple 2 domain of FXI and inhibits FXI activation by factor XIIa (FXIIa), while not significantly inhibiting its activation by thrombin or the ability of FXIa to activate factor IX. 1A6 binds to the apple 3 domain and inhibits the feedback activation of FXI by thrombin as well as the activation of FIX by FXIa. Pre-treatment of baboons with 14E11, 1A6 (both 100 μg/kg, iv bolus), or the low-molecular-weight heparin enoxaparin (0.7 mg/kg iv bolus + 0.3 mg/kg/hr continuous infusion), prolonged the aPTT of baboons up to 3-fold. The antithrombotic effect of the anticoagulants were evaluated by measuring the accumulation of platelets and fibrin within high shear collagen-coated vascular graft segments (4mm i.d.), which models arterial-type thrombosis, as well as in a distal silicone expansion chamber (9mm i.d.) positioned downstream of the graft, which models the slower flow profile of venous thrombosis. The thrombogenic devices were deployed into flow restricted (100ml/min) chronic arteriovenous shunts for 1 hour. The treatments reduced platelet accumulation within the thrombus expansion chamber by 89%, 94%, and 93% in 14E11-, 1A6-, and enoxaparin-treated animals, respectively (P<0.001, n=5–6 for each treatment). Fibrin accumulation was also comparably lower by 80–90% in all treatment groups. While both 14E11 and 1A6 were remarkably efficacious against venous-type thrombogenesis, 1A6 was more antithrombotic than 14E11 in the higher shear proximal grafts that accumulate platelet-rich arterial-type thrombi (P=0.001, 14E11 vs. 1A6). The antithrombotic efficacy of 14E11 indicates that FXI activation by FXIIa may be a sufficient driver for acute venous thrombosis, whereas the efficacy of 1A6 to limit both arterial-and venous-type thrombogenesis indicates that the feedback activation of FXI by thrombin may be an important driver for arterial thrombosis. These data suggest that the mechanism of FXI activation and/or activity may vary depending on the different shear and flow conditions that occur during venous and arterial thrombosis. The effect of anticoagulation on hemostasis was assessed by measuring the template bleeding time (BT) in conjunction with high dose aspirin treatment (32 mg/kg). The average BT was not significantly increased by the FXI antibodies or enoxaparin treatment alone. Aspirin increased the BT by 51% (from 3.5±0.4min to 5.3±0.9min), while co-administration of aspirin with enoxaparin further increased the BT by 66% to 8.8±0.6min. Co-administration of aspirin with 14E11 or 1A6 resulted in BTs that were statistically indistinguishable from the BT prolongation with aspirin alone (4.9±0.7 min and 5.2±0.5 min respectively). Thus, in the presence of aspirin, anticoagulation by inhibiting plasma FXI procoagulant activity (1A6) or the FXI-mediated procoagulant activity of FXIIa (14E11) was hemostatically safer than anticoagulation with enoxaparin. In summary, our data suggest that targeting specific molecular pathways at the FXI/FXII axis with inhibitors specific for FXI apple domains may help delineate the roles of FXI in thrombosis and hemostasis, and that selective inhibition of FXIa activity or FXI activation may be effective and safer than enoxaparin for pharmacological thromboprophylaxis. Disclosures: Tucker: Aronora, LLC: Employment, Equity Ownership. Leung:Aronora, LLC: Employment. Verbout:Aronora, LLC: Employment. Gruber:Aronora, LLC: Consultancy, Equity Ownership." @default.
• W2564387316 created "2017-01-06" @default.
• W2564387316 creator A5011450008 @default.
• W2564387316 creator A5021496734 @default.
• W2564387316 creator A5027011914 @default.
• W2564387316 creator A5028956784 @default.
• W2564387316 creator A5032261187 @default.
• W2564387316 creator A5035974662 @default.
• W2564387316 creator A5036237322 @default.
• W2564387316 creator A5050978437 @default.
• W2564387316 creator A5084568262 @default.
• W2564387316 date "2011-11-18" @default.
• W2564387316 modified "2023-09-27" @default.
• W2564387316 title "Apple Domain-Specific Anti-Factor XI Antibodies Inhibit Venous-Type Thrombosis with Improved Hemostatic Safety Profiles Compared to Enoxaparin in Primates" @default.
• W2564387316 doi "https://doi.org/10.1182/blood.v118.21.1173.1173" @default.
• W2564387316 hasPublicationYear "2011" @default.
• W2564387316 type Work @default.
• W2564387316 sameAs 2564387316 @default.
• W2564387316 citedByCount "0" @default.
• W2564387316 crossrefType "journal-article" @default.
• W2564387316 hasAuthorship W2564387316A5011450008 @default.
• W2564387316 hasAuthorship W2564387316A5021496734 @default.
• W2564387316 hasAuthorship W2564387316A5027011914 @default.
• W2564387316 hasAuthorship W2564387316A5028956784 @default.
• W2564387316 hasAuthorship W2564387316A5032261187 @default.
• W2564387316 hasAuthorship W2564387316A5035974662 @default.
• W2564387316 hasAuthorship W2564387316A5036237322 @default.
• W2564387316 hasAuthorship W2564387316A5050978437 @default.
• W2564387316 hasAuthorship W2564387316A5084568262 @default.
• W2564387316 hasConcept C126322002 @default.
• W2564387316 hasConcept C164705383 @default.
• W2564387316 hasConcept C203014093 @default.
• W2564387316 hasConcept C2777292125 @default.
• W2564387316 hasConcept C2777557582 @default.
• W2564387316 hasConcept C2778589496 @default.
• W2564387316 hasConcept C2779394231 @default.
• W2564387316 hasConcept C2780011451 @default.
• W2564387316 hasConcept C2780868729 @default.
• W2564387316 hasConcept C3018697912 @default.
• W2564387316 hasConcept C54173615 @default.
• W2564387316 hasConcept C71924100 @default.
• W2564387316 hasConcept C89560881 @default.
• W2564387316 hasConcept C98274493 @default.
• W2564387316 hasConceptScore W2564387316C126322002 @default.
• W2564387316 hasConceptScore W2564387316C164705383 @default.
• W2564387316 hasConceptScore W2564387316C203014093 @default.
• W2564387316 hasConceptScore W2564387316C2777292125 @default.
• W2564387316 hasConceptScore W2564387316C2777557582 @default.
• W2564387316 hasConceptScore W2564387316C2778589496 @default.
• W2564387316 hasConceptScore W2564387316C2779394231 @default.
• W2564387316 hasConceptScore W2564387316C2780011451 @default.
• W2564387316 hasConceptScore W2564387316C2780868729 @default.
• W2564387316 hasConceptScore W2564387316C3018697912 @default.
• W2564387316 hasConceptScore W2564387316C54173615 @default.
• W2564387316 hasConceptScore W2564387316C71924100 @default.
• W2564387316 hasConceptScore W2564387316C89560881 @default.
• W2564387316 hasConceptScore W2564387316C98274493 @default.
• W2564387316 hasLocation W25643873161 @default.
• W2564387316 hasOpenAccess W2564387316 @default.
• W2564387316 hasPrimaryLocation W25643873161 @default.
• W2564387316 hasRelatedWork W1983261646 @default.
• W2564387316 hasRelatedWork W1989883128 @default.
• W2564387316 hasRelatedWork W1995845349 @default.
• W2564387316 hasRelatedWork W2004761712 @default.
• W2564387316 hasRelatedWork W2011416642 @default.
• W2564387316 hasRelatedWork W2025166282 @default.
• W2564387316 hasRelatedWork W2028460241 @default.
• W2564387316 hasRelatedWork W2055085177 @default.
• W2564387316 hasRelatedWork W2072344433 @default.
• W2564387316 hasRelatedWork W2094839530 @default.
• W2564387316 hasRelatedWork W2097908856 @default.
• W2564387316 hasRelatedWork W2104391363 @default.
• W2564387316 hasRelatedWork W2117944864 @default.
• W2564387316 hasRelatedWork W2161349379 @default.
• W2564387316 hasRelatedWork W2302714844 @default.
• W2564387316 hasRelatedWork W2333637561 @default.
• W2564387316 hasRelatedWork W2398281760 @default.
• W2564387316 hasRelatedWork W2410830944 @default.
• W2564387316 hasRelatedWork W2560008656 @default.
• W2564387316 hasRelatedWork W3046297343 @default.
• W2564387316 isParatext "false" @default.
• W2564387316 isRetracted "false" @default.
• W2564387316 magId "2564387316" @default.
• W2564387316 workType "article" @default.